225 related articles for article (PubMed ID: 30384349)
21. Basics of Compounding: Clinical Pharmaceutics, Part 2.
Allen LV
Int J Pharm Compd; 2016; 20(6):485-493. PubMed ID: 28339388
[TBL] [Abstract][Full Text] [Related]
22. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
23. A new paradigm for improving oral absorption of drugs in discovery: role of physicochemical properties, different excipients and the pharmaceutical scientist.
Wilson AG; Nouraldeen A; Gopinathan S
Future Med Chem; 2010 Jan; 2(1):1-5. PubMed ID: 21426039
[No Abstract] [Full Text] [Related]
24. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance: Part 1-Effects on Solubility of Poorly Soluble Drugs.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS PharmSciTech; 2020 Jun; 21(5):177. PubMed ID: 32592045
[TBL] [Abstract][Full Text] [Related]
25. Particle Engineering for Enabling a Formulation Platform Suitable for Manufacturing Low-Dose Tablets by Direct Compression.
Sun WJ; Aburub A; Sun CC
J Pharm Sci; 2017 Jul; 106(7):1772-1777. PubMed ID: 28322940
[TBL] [Abstract][Full Text] [Related]
26. Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: A Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States.
Lobb WB; Wilkin NE; Holmes ER
Int J Pharm Compd; 2015; 19(6):514-20. PubMed ID: 26891565
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations.
Visser JC; Ten Seldam IEJ; van der Linden IJ; Hinrichs WLJ; Veenendaal RFH; Dijkers ECF; Woerdenbag HJ
Int J Pharm Compd; 2018; 22(3):247-251. PubMed ID: 29878892
[TBL] [Abstract][Full Text] [Related]
28. Compounding slow-release capsules: a comprehensive review and an Excel spreadsheet for faster calculations of excipients.
Zur E
Int J Pharm Compd; 2013; 17(1):10-22. PubMed ID: 23627242
[TBL] [Abstract][Full Text] [Related]
29. Mixing In a Compounding Pharmacy in the 21st Century.
Standridge R
Int J Pharm Compd; 2015; 19(6):479-84. PubMed ID: 26891562
[TBL] [Abstract][Full Text] [Related]
30. The Most Useful Pharmaceutical Formulations (Individualized Medications) in Pediatric Dermatology: A Review.
Abarca Lachén E; Hernando Martínez P; Gilaberte Calzada Y
Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):302-313. PubMed ID: 33220314
[TBL] [Abstract][Full Text] [Related]
31. Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients.
Allen LV
Int J Pharm Compd; 2023; 27(6):474-481. PubMed ID: 38100665
[TBL] [Abstract][Full Text] [Related]
32. Drug loading of nanoporous TiO2 films.
Ayon AA; Cantu M; Chava K; Agrawal CM; Feldman MD; Johnson D; Patel D; Marton D; Shi E
Biomed Mater; 2006 Dec; 1(4):L11-5. PubMed ID: 18458401
[TBL] [Abstract][Full Text] [Related]
33. Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome(.).
Aragao-Santiago L; Bohr A; Delaval M; Dalla-Bona AC; Gessler T; Seeger W; Beck-Broichsitter M
Curr Pharm Des; 2016; 22(9):1147-60. PubMed ID: 26675224
[TBL] [Abstract][Full Text] [Related]
34. Devices for securing and administering pediatric compounded oral liquids: survey results from French university hospitals.
Cavelier M; Hervouët C; Varin R; Gondé H
Eur J Pediatr; 2024 Jun; 183(6):2805-2810. PubMed ID: 38573361
[TBL] [Abstract][Full Text] [Related]
35. Exploring paediatric oral suspension development: Challenges, requirements, and formulation advancements.
Gaikwad SS; Morales JO; Lande NB; Catalán-Figueroa J; Laddha UD; Kshirsagar SJ
Int J Pharm; 2024 May; 657():124169. PubMed ID: 38688428
[TBL] [Abstract][Full Text] [Related]
36. Co-administration of Paediatric Medicines with Food and Drinks in the Context of Their Physicochemical Properties-a Global Perspective on Practices and Recommendations.
Martir J; Flanagan T; Mann J; Fotaki N
AAPS J; 2020 Mar; 22(2):54. PubMed ID: 32133550
[TBL] [Abstract][Full Text] [Related]
37. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
Srinarong P; de Waard H; Frijlink HW; Hinrichs WL
Expert Opin Drug Deliv; 2011 Sep; 8(9):1121-40. PubMed ID: 21722000
[TBL] [Abstract][Full Text] [Related]
38. Application of silicified microcrystalline cellulose (Prosolv) as a polymer carrier of Epilobium parviflorum Schreb. extract in oral solid drug form.
Marczyński Z; Zgoda MM; Jambor J
Polim Med; 2007; 37(2):21-32. PubMed ID: 17957946
[TBL] [Abstract][Full Text] [Related]
39. Carrageenan as an efficient drug release modifier for ethylcellulose-coated pharmaceutical dosage forms.
Siepmann F; Muschert S; Zach S; Leclercq B; Carlin B; Siepmann J
Biomacromolecules; 2007 Dec; 8(12):3984-91. PubMed ID: 18039003
[No Abstract] [Full Text] [Related]
40. Cyclodextrin-Based Formulations: A Non-Invasive Platform for Targeted Drug Delivery.
Muankaew C; Loftsson T
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):46-55. PubMed ID: 29024354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
